According to the research report titled ‘Global Anticoagulant Reversal Drugs Market Size study, by Drug Class (Prothrombin Complex Concentrates, Coagulation Factors, Monoclonal Antibodies, Phytonadione and Others), and Regional Forecasts 2020-2026’, available with Market Study Report, global anticoagulant reversal drugs market was worth USD 811.56 million in 2019 and is expected to grow with a CAGR of 15.6% during 2019-2026.
 

For the record, anticoagulant medicines are used to prevent blood clotting as well as to reverse or balance bleeding. These drugs help in reducing the risks associated with unplanned surgery or an overdose of anticoagulant therapy. The product also aids in avoiding serious conditions including heart attacks and strokes among patients suffering from clotting disorder.
 

The product is widely used in treating cardiovascular conditions since it removes or dissolves blood clots. Increased pervasiveness of cardiovascular diseases is a major factor driving the growth of worldwide anticoagulant reversal drugs industry.
 

According to World Health Organization (WHO), cardiovascular diseases are a major cause of deaths across the globe, totaling to 17.9 million or 31% of global death each year. Growing elderly population and rising issues pertaining to blood clots have augmented the adoption of anticoagulant reversal drugs, which in turn is fueling the market size. However, high costs of patented drugs may act as a restraining factor to the overall market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2610795/
 

As per drug class, anticoagulant reversal drugs industry is classified into phytonadione, monoclonal antibodies, coagulation factors, prothrombin complex concentrates and others.
 

Citing the regional scope, North America holds a majority share in global anticoagulant reversal drugs industry. Rising prevalence of cardiovascular diseases is fostering the regional demand.
 

Meanwhile, anticoagulant reversal drugs industry in Asia-Pacific is predicted to grow substantially during the forecast period, primarily due to rising geriatric population across emerging nations.
 

The key participants in global anticoagulant reversal drugs market are Perosphere Pharmaceuticals Inc., Fresenius Kabi Ag, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Pfizer Inc., CSL Behring Ltd., Boehringer Ingelheim GmbH and Portola Pharmaceuticals Inc. among others.